Stockpolly
Search
Delisting risk
CNTX · NASDAQ · Biotechnology

Context Therapeutics (CNTX)

Develops CD3-directed bispecific antibodies for solid tumors.

$0.3517
Pre-market−0.01 (−4.01%)
At close$0.3664(+0.58%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
67431946101114915
Research & development452117338912713
222222222222
General & administrative222222222222
Operating income−6−7−4−3−19−4−6−10−11−14−9−15
000111111110
Interest income000111111110
Other non-operating income000−1−1−1−1−1−1−1−10
Income before tax−6−7−4−2−17−3−5−9−10−13−9−15
Net income from continuing operations−6−7−4−2−17−3−5−9−10−13−9−15
Net income−6−7−4−2−17−3−5−9−10−13−9−15
EPS, basic−$0.37−$0.42−$0.23−$0.04−$0.22−$0.06−$0.05−$0.09−$0.10−$0.14−$0.09−$0.15
EPS, diluted−$0.37−$0.42−$0.23−$0.04−$0.22−$0.06−$0.05−$0.09−$0.10−$0.14−$0.09−$0.15
Weighted average shares, basic161616558058959595929595
Weighted average shares, diluted161616558058959595929595
EBITDA−6−7−4−2−17−3−5−9−10−13−9−15
Depreciation & amortization000000000000
EBIT−6−7−4−2−17−3−5−9−10−13−9−15